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a  b  s  t r  a  c  t
During  the last  quarter  of the  past  century,  the  leading  role  the endocrine  and  nervous  systems  had  on
the  regulation  of vasomotion,  shifted  towards  a more  paracrine-based  regulation.  This begun  with  the
recognition  of endothelial  cells  as  active  players  of  vascular  control,  when  the vessel’s  intimal  layer  was
identiﬁed  as the  main  source  of  prostacyclin  and  was  followed  by the discovery  of  an  endothelium-derived
smooth  muscle  cell  relaxing  factor  (EDRF).  The  new  position  acquired  by  endothelial  cells  prompted
the  discovery  of  other  endothelium-derived  regulatory  products:  vasoconstrictors,  generally  known  as
EDCFs,  endothelin,  and  other  vasodilators  with  hyperpolarizing  properties  (EDHFs).  While  this  research
was  taking  place,  a  quest  for the  discovery  of the  nature  of EDRF  carried  back  to  a research  line  com-
menced  a  decade  earlier:  the  recently  found  intracellular  messenger  cGMP  and  nitrovasodilators.  Both
were smooth  muscle  relaxants  and  appeared  to  interact  in a hormonal  fashion.  Prejudice  against  an
unconventional  gaseous  molecule  delayed  the  acceptance  that  EDRF  was  nitric  oxide  (NO).  When  this
happened,  a new  era  of  research  that  exceeded  the vascular  ﬁeld  commenced.  The  discovery  of the path-
way for  NO  synthesis  from  L-arginine  involved  the clever  assembling  of  numerous  unrelated  observations
of  different  areas  of  knowledge.  The  last  ten years  of research  on  the  paracrine  regulation  of  the  vascu-
lar wall  has  shifted  to perivascular  fat (PVAT),  which  is  beginning  to be regarded  as  the  fourth  layer  of
the  vascular  wall.  Starting  with the  discovery  of an  adipose-derived  relaxing  substance  (ADRF),  the  role
that different  adipokines  have  on the  paracrine  control  of  vasomotion  is now  ﬁlling  the  research  activity
of  many  vascular  pharmacology  labs,  and surprising  interactions  between  the  endothelium,  PVAT  and
smooth  muscle  are  being  unveiled.© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
During much part of last century, vasomotion, i.e.: change in
he vessel’s diameter, was thought to be mostly regulated by the
utonomous nervous system and hormones released by speciﬁc
lands. An alternative to this was proposed during the late forties
nd early ﬁfties by Jimenez-Díaz and colleagues who, by means of
ross-circulation experiments, demonstrated the endocrine role of
he vessel wall [1,2]. However, no hormonal function was assigned
o speciﬁc vascular structures until much later. The concept of
aracrine secretion was introduced by this time because it was
onvenient for distinguishing locally-acting gastrointestinal hor-
ones from systemically-acting hormones [3] but the term was not
f general use in physiology as it is today. The ﬁrst substance able
o dilate vascular smooth muscle synthesized and released by the
essels themselves was described in the mid-seventies [4]. This was
rostacyclin [5]. With the turn of the decade, the endothelial cell of
he vascular intimal layer was speciﬁcally pinpointed as essential
or the relaxation of adjacent smooth muscle cells [6]. The concep-
ion of an endothelial cell releasing substances that preferentially
ffect nearby smooth muscle cells, i.e.: paracrine regulation, was
xtended during the eighties to a variety of substances, includ-
ng prostacyclin and nitric oxide (NO), which is probably the one
hat has received more attention. With this panorama in sight, the
ndothelium was  proposed as a real endocrine organ [7]. While
ndothelial cells had gained a prominent role as regulators of vaso-
otion and various other functions, other vascular cells timidly
btained the qualiﬁcation of paracrine regulatory cells. The ﬁrst to
reak the ice was not, as one would initially think, the anatomically
mmediate adventitial ﬁbroblast, but rather, the outermost perivas-
ular fat tissue [8]. This opening work [8] had to wait until 2002,
hen the burst of perivascular fat research took place [9]. In the
eanwhile, new roles for adventitial cells as a source of substances
egan to be assigned [10].
In this review we will search for the seminal advances and
ioneering work that yielded the knowledge we have today on
he major paracrine elements controlling vascular smooth muscle
ontraction or relaxation. These are, the endothelium-derived sub-
tances: NO, prostacyclin, contracting and hyperpolarizing factors
nd the, relatively newer, substances released by the adventitia and
erivascular adipose tissue. A chronological order of reporting has
een given priority to a more academic order. Occasionally, this can
ppear odd at reading. For example, for the endothelium-derived
elaxing factor (EDRF)-NO topic, NO is not explained right away
fter EDRF because nearly a decade of contracting and hyperpolar-
zing factor research took place in between. In some occasions, the
reliminary work necessary for a subsequent discovery took place
uite a long time and with, apparently, little connection with the
atter. In many instances, various groups published so closely in
ime to the report traditionally recognized as the ﬁrst and principal
hat it is easy to conceive that work aimed at the same target was
eing carried out in parallel. Often, an idea is more or less vaguely
uggested in preliminary works and deﬁnitely demonstrated by
he same or other authors in subsequent reports. In the present
eview we have tried to quote every report related or involved in a
iscovery and not solely that generally recognized as the ﬁrst one.
. Early approaches to the paracrine role of the intima
The existence of endothelial cells was ﬁrst reported by von Reck-
nghausen in 1860. The German pathologist managed to observe the
ndothelial lining of the vessel’s inner wall by staining the edges of
ndothelial cells with silver nitrate [11]. From then on and for many
ears, the endothelium was regarded, more or less, as a tapestry
acking any functional role. For example, at the sight of some ofResearch 113 (2016) 125–145
the ﬁrst electron microscope plates, endothelial cells were literally
described as “. . .to form little more than a sheet of nucleated cel-
lophane” [12]. Nevertheless, early electron microscopist, Rhodin,
intuitively suggested that “. . .humoral transmitter substances [. . .]
are picked up by the luminal cell membrane of the endothelial cell and
passed on to the smooth muscle cells. . .”. This seemed to be a prelude
of some kind of regulatory function [13]. Furthermore, some phar-
macologists reported shortly later intriguing ﬁndings that were not
consistent with a passive notion of endothelial function. Bevan &
Duckles, for instance, realized that noradrenaline bound to glass
microbeads present in the vascular lumen and, therefore, unable
to reach the smooth muscle wall, did elicit a contractile effect [14].
They reasoned that the only way this could happen was if endothe-
lial cells had surface receptors to the amine and endothelial cells
had a mechanism of spread towards the underlining muscle cells.
They raised the possibility that circulating drugs initiate changes
in the tone of vascular smooth muscle by an action on the inti-
mal  endothelial cells [14] by means of receptors on these cells that
would be the ﬁrst to detect blood-borne vasoactive substances [15].
In those years, the existence of receptors to a variety of vasoac-
tive agents on endothelial cell membranes and linked to cAMP and
cGMP was already known [16]. Thus, the scenario for discovery was
ready.
Another suggestive ﬁnding, both for the putative paracrine roles
of intimal and adventitial cells, was  the observation that the effects
of contractile amines was very different when applied via the
intimal side or through the adventitial side [17,18]. Vessels were
systematically more sensitive when exposed through the intima.
Among others, one of the explanations they considered was  that
the different vascular layers the drug had to cross, intima and
adventitia, carried out some sort of active role. Unfortunately, this
suspected active role was  tested only in the adventitia, by specif-
ically removing it [19], but not in the intimal endothelial cells, as
Furchgott did very shortly later [6]. They missed an opportunity for
an important discovery.
3. Prostacyclin
Prostacyclin, together with thromboxane A2 (TXA2) and vari-
ous prostaglandins are synthesized from arachidonic acid, a fatty
acid derived from membrane phospholipids. Endoperoxides are
intermediate molecules between arachidonic acid and the various
prostanoids. Enzymes cyclooxygenase I and II catalyze the forma-
tion of these endoperoxides. Prostacyclin was discovered in 1976
by the group led by Vane [4]. Vane’s interest in prostaglandins dates
back to the late sixties studying anaphylactic responses of perfused
lungs from sensitized guinea pigs and the different substances
thereby released, such as histamine, slow-reacting substance in
anaphylaxis (SRS-A) and also prostaglandin-like substances [20].
One of these was  the so-called, “rabbit aorta contracting substance”
or RCS, because it caused a strong contraction of strips of rabbit
aorta. This was later identiﬁed as TXA2 [21], a powerful proaggre-
gatory and vasoconstritive mediator, and the synthesizing enzyme,
“thromboxane synthetase”, was isolated from the “microsomal”
fraction of platelets [22]. Eventually, the group began to study other
tissues in an attempt to ﬁnd alternative sources of TXA2 gener-
ation. John Vane explains how they came across an unexpected
ﬁnding [23]: “It was Moncada’s suggestion that we should look into
the biosynthetic system of vascular tissue, since vascular endothelium
and platelets might share some structural features. Indeed, after several
weeks of work we found that microsomal fractions of pig aorta [. . .]
did not generate classical prostaglandins”. The prostaglandin found
in the vascular tissue, deﬁnitely was not TXA2, but a substance
with opposite properties: an anti-aggregating and vasodilator sub-
stance. It did not take too long until the chemical structure of the
E. Nava, S. Llorens / Pharmacological 
Fig. 1. Differential generation of prostacyclin by the layers of the vessel wall.
The ﬁrst to attribute a functional role to the endothelium were early prostacyclin
researchers showing that endothelial cells are the most important, if not the only










































d% of the calculated weight, produced about 40% of the total vessel’s prostacyclin.
he other layers contribute to the 60% prostacyclin left, but represent 95% of the
rtery’s weight. Modiﬁed from Moncada et al. [26].
ew prostanoid was identiﬁed and renamed prostacyclin (PGI2)
24]. It was also shown that the actions of prostacyclin are medi-
ted by the adenylate cyclase/cyclic AMP  pathway [25] and that,
ith a half-life long enough to reach distant targets, it could be
egarded as a circulating hormone as well [5]. The ﬁrst report on
he newly discovered prostacyclin, still called PGX [4], was remark-
bly mature in that today’s well established concepts of physiology
extbooks on the role of platelets and endothelial cells in hemosta-
is were already stated in this seminal paper. Especially relevant for
he topic of the present review is that this paper also put forward
he notion of a paracrine control of the tone of the vessel wall: “The
act that PGX is locally generated in the arterial wall and can relax
mooth muscle also suggests that it plays a part in the local control of
ascular tone”. Shortly after this publication, the differential forma-
ion of prostacyclin by the different layers of the vessel wall was
eported by this group [26] showing this is highest in the endothe-
ial layer, thus providing the endothelium for the ﬁrst time a leading
ole in the local control of vascular tone (Fig. 1). Still, and maybe
onfounded by the fact the media and adventitia also released some
rostacyclin [26], the notion of an endothelially-centered control
f vascular tone, could not be established. Ironically, another group
ublishing a little bit later was unable to detect prostacyclin release
rom smooth muscle or any other cell studied but endothelial cells
27]. If Vane’s group had failed to ﬁnd prostacyclin synthesis in the
edia, possibly the leadership of the endothelial cell had become
arlier.
. Endothelium-derived relaxing factor
In the immediate years following Vane’s publications, the pro-
uction of prostacyclin by the intimal or other vascular layers was
ostly observed from the point of view of the anti-aggregating
roperties of the new prostaglandin able to counterbalance
latelets’ TXA2. From this angle, an endothelial damage was
egarded as a hemostatic rather than a vasomotor threat. Thus,
xperimentation on vascular pharmacology was still carried out
gnoring the endothelium. The ﬁrst to change this scenario were
urchgott and Zawadszki with the publication in 1980 of “The oblig-
tory role of endothelial cells in the relaxation of arterial smooth
uscle by acetylcholine” [6]. This paper was very remarkable in that
n a single seminal report, providing unequivocal experimental evi-
ence, demonstrated that acetylcholine required the presence ofResearch 113 (2016) 125–145 127
an intact endothelium to exert vasodilatory effects on the adjacent
smooth muscle (Fig. 2). Also that, via receptors on the endothelial
cells, acetylcholine stimulates the release of a transferable sub-
stance which causes relaxation of the vessel wall. For these reasons,
this work became the major milestone for vascular pharmacology
and physiology research and was the most cited original paper in
this ﬁeld (6569 citations). Interestingly, Furchgott admits that the
ﬁnding was quite accidental [28]: “. . .in the very ﬁrst experiment
of this planned series in May 1978, my technician did not follow my
directions correctly: [. . .]  he tested carbachol for its contracting activ-
ity before rather than after (as prescribed in the directions) washout of
a previous test dose of norepinephrine. The response to carbachol was
not a contraction, but was a partial relaxation [. . .].  Acetylcholine was
then tested. It too produced relaxation of the aortic preparation pre-
contracted with norepinephrine. This was the ﬁrst time that I had ever
observed relaxation of rabbit aorta in response to muscarinic agonists
over the many years that I had been using this blood vessel.  . .”. They
were expecting acetylcholine to contract, but by mistake the tech-
nician added the cholinergic agonist on top of an artery that should
not have been precontracted. To Furchgott’s surprise, a relaxation
took place. Indeed, acetylcholine had shown vascular contractile
responses in vitro since ever tested [29]. Still, Furchgott was con-
scious and that, for unknown reasons, vasodilator responses to
acetylcholine had been occasionally detected [30] and, more impor-
tantly, that acetylcholine in vivo causes vasodilation [31]. The key
to understand how Furchgott suspected that the answer was in the
endothelial cells relies on the fact that in that set of experiments,
they used intact aortic rings instead of spiral strips. Normally, he
cut the arterial strips in a helical fashion and then he measured
the force attained by hooking the edges to the myograph devise.
To facilitate the cutting procedure he (and most pharmacologists)
systematically introduced a wire through the lumen of the arteries,
unaware that the endothelium was  being damaged or removed. In
fact, still today, introducing a rod or similar is a conventional proce-
dure to deendothelialize a vessel. This was their regular procedure,
but not the day the technician erred, in which an intact ring was
tested. The original recording of the serendipitous ﬁnding can be
found in ref. 28. A preliminary report on these ﬁndings, prior to the
1980 paper, was an abstract from a 1979 meeting [32] in which,
surprisingly, he revealed too many clues of the discovery.
Very shortly after Furchgott & Zawadszki’s paper, a couple of
groups corroborated the endothelium ﬁndings. De  Mey  & Van-
houtte described the role of the intima in various responses
including cholinergic, purinergic and thrombin relaxations [33,34].
This last paper started the listing of substances that elicit vasodi-
lation via the endothelium and initiated the speculations on the
nature of the endothelium-to-smooth muscle signals causing relax-
ation. Another report published nearly at the same time was that
of Altura and Chand who were concerned about the unmatched
in vitro versus in vivo effects of some agonists, in this case, kinins
[35]. A year later, Furchgott, also interested in the endothelial
mechanisms of bradykinin, reached similar conclusions as those
of Altura and Chand on the endothelium-dependency of the kinin’s
action [36]. In this paper, Furchgott introduced for the ﬁrst time
the term “endothelium-derived relaxing factor” and its acronym
“EDRF” to refer to a substance released from endothelial cells
and able to relax the muscle. Substance P was also added to the
growing list of hormones, which relax via endothelium. Another
novelty of this paper was  the ﬁrst report of EDRF in human arter-
ies. Furchgott’s group also provided the ﬁrst preliminary insights
on the calcium-dependency of EDRF by examining the effects of the
calcium ionophore A23187 on the endothelium-dependent relax-
ations [37], an issue that was  later investigated in more depth [38].
128 E. Nava, S. Llorens / Pharmacological Research 113 (2016) 125–145
Fig. 2. Seminal experiments performed by Furchgott and Zawadzki led, beyond any doubt, to the conclusion that endothelial cells, upon acetylcholine stimulation, release
in  a paracrine manner a substance that reaches smooth muscle cells to relax them (EDRF). Arteries were cut along and attached to a myograph. A, B and C represent various


































Artery  2 (smooth muscle 2). Author’s micrographs of intact and deendothelialized ar
reparations. Note alignment of endothelial and smooth muscle cells with respect 
o  acetylcholine in rubbed strips have been omitted for simplicity. Acetylcholine w
. Endothelium-derived constrictor factor
The realization of the existence of endothelium-dependent
asoconstriction took place early after Furchgott’s publication and
as somehow linked to the discovery of EDRF. Possibly the main
ifference was that the ﬁnding of EDRF was serendipitous in nature
nd the uncovering of the existence of the constrictor counterpart
ook part under a speciﬁc rationale: the attempt to clarify why
n some instances acetylcholine relaxed a vessel, and contracted
n others. Vanhoutte and De Mey  were studying the mechanisms
nvolved in the unexplained relaxations to acetylcholine in certain
et-ups. One of these was anoxia, which they knew from previous
tudies that is able to augment catecholamine-induced contractile
esponses. Just before the publication of Furchgott’s 1980 paper,
hey found that anoxia abolished the relaxing responses to acetyl-
holine [39]. Once knowing about the role of endothelial cells
rom Furchgott’s studies, they took up the topic and published a
hort report which, in addition to conﬁrming the obligatory roles
f the endothelium, they also indicated that the augmented cate-
holamine contractile responses caused by subjecting the vessels
o hypoxic conditions depended on the preservation of a functional
ndothelium [40]. The notion that the endothelium contributes, not
olely to smooth muscle relaxation, but in some instances, to con-
ractile responses was matured in following studies [41] and ﬁnally,
he ﬁrst evidence that anoxia causes the release of a diffusible
asoconstrictor substance from endothelial cells, was published by
anhoutte and Rubanyi in 1985 [42].
By the same time, Rubanyi together with Hickey and other
olleagues were also working on a bioassay system aimed to
dentify the chemical nature of EDRF. They worked in a bioassay
et-up in which the donors of the relaxing factor were cultured
ndothelial cells and the detectors were luminally rubbed arterial
ings challenged with the medium from the endothelial culture.
gainst expectations, what they found were not relaxations but, stained with silver nitrate have been used to exemplify the different myographical
ograph orientation. Pre-contraction with noradrenaline and eventual contractions
ed in cumulative doses from 10−8 to 10−5 M.
instead, that the acceptor rings consistently contracted. They pur-
sued the studies trying to uncover the nature of the transferable
substance and found that the contracting agent was compatible
with a polypeptide [43]. This was the prelude of endothelin, the
name Yanagisawa and his colleagues decided to give to the pep-
tidic vasoconstrictor present in the endothelial culture medium
once puriﬁed and sequenced [44]. Before this, the peptidic nature
of the vasoconstrictor reported by the Hickey group was conﬁrmed
by Gillespie et al. who introduced the acronym EDCF in the liter-
ature to distinguish it from EDRF [45]. In a nice review published
a few years ago, Rubanyi admits that the peptidic substance they
discovered was  nearly named “endotensin”, but unfortunately, this
was discarded in the reviewing process of the manuscript [46] and
it ended up being called endothelin [44].
In parallel to the endothelin work, Vanhoutte kept work-
ing on the lines initiated with hypoxia. He did not believe that
endothelin was the only answer to the endothelium-dependent
contractions [47]. One of the lines started with a 1985 paper
showing that endothelial cyclooxygenase generates vasoconstric-
tor prostaglandins [48], which were speciﬁcally ascribed to TXA2
in a following paper by Altiere and coworkers [49]. Shortly
afterwards, Lüscher published his classic paper for endothelial dys-
function showing that in the aorta of hypertensive rats, and due to
an excess in vasoconstrictor prostaglandins, acetylcholine causes
endothelium-dependent contractions rather than relaxations [50].
During the following years Vanhoutte’s group was  engaged
in a quest to pinpoint the contractile prostaglandin. Also, they
embarked in a second line of research that introduced reac-
tive oxygen species in the pathway of prostaglandins and the
endothelium-dependent contractions. This line started rather cat-
egorical, proposing superoxide anion as EDCF [51]. This was
not the ﬁrst report on reactive oxygen species, prostanoids and
vasoconstriction. It was already known that endothelial cells gen-
erate superoxide [52] and a few years before, Tate and others
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Fig. 3. Depiction of endothelium-derived paracrine vasoactive factors commented and referenced in the text. Agonist (A), receptor (R), cytochrome P-450 epoxygenases
(P450), cyclooxygenases (COX), endothelial NO synthase (eNOS), endothelin-converting enzyme (ECE), epoxyeicosatrienoic acids (EETs), thromboxane A2 (TXA2), prostacyclin
(PGI2), TXA2 receptor (TP), PGI2 receptor (IP), calcium-dependent K+ channel (KCa), smooth muscle cell (SMC), endothelial cell (EC).
Reference matching (ﬁrst author followed by year abbreviation): a Hecker ‘94; Campbell ‘96 [78,79], b Svensson ‘75 [21], c Moncada ‘76 [4], d Miller ‘85; Altiere ‘86 [48,49],



































fatoba ‘00 [76,77], j Tare ‘90 [74], k Zawadzki ‘80; Singer ‘82 [37,38], l Palmer ‘89
rnold  ‘77, [106,107], o Katsuki ‘77b*; Kukovetz ‘79 [110,112], p Gordon ‘83 [67], q 
uscle, which was  tested before vascular smooth muscle.
eported that oxygen metabolites cause vasoconstriction of pul-
onary arteries via TXA2 [53]. After the start-up of the superoxide
ine, numerous publications trying to elucidate the link between
ndothelial activation, oxygen species generation, prostaglandin
ynthesis and ﬁnally smooth muscle contraction, followed. Most
eports, such as that of Cosentino and coworkers [54] coincided
n various aspects: a) the endothelial cell, when activated with
cetylcholine would generate oxygen radicals which would in turn
ctivate a cyclooxygenase that oversynthesizes all prostaglandins.
) Neither TXA2 nor PGI2 seemed to be the prostaglandins respon-
ible. c) Most papers concurred in that TXA2 receptor blockade on
he smooth muscle cell reverted the contractile process and ﬁnally,
) the whole process, although present in healthy vessels, is exac-
rbated in hypertension. The problem of the sequence of events
aking place from the initial acetylcholine activation with an intra-
ellular calcium increase to the ﬁnal contraction of the vessel was
esumed a few years ago using state-of-the-art methodology. By
eans of intracellular imaging, it was demonstrated that cyclooxy-
enase activation occurs upstream of the generation of oxygen
adicals [55]. One thing that was surprising in this report is that
he traditional sequence of events (oxygen radical generation fol-
owed by cyclooxygenase activation) was inverted. A more recent
eport, elegantly resolves the debate on the order of events by
howing the existence of a feedback loop between reactive oxygen
pecies and cyclooxygenase-2. Under this scheme, one modulates
he other and vice versa [56] (Fig. 3). As stated before, the research
n prostaglandins as EDCFs continued in parallel with the superox-
de topic, and often both coincided in the same paper. For instance,
 1990 paper insisted in that oxygen-derived free radicals might be
DCFs and would cause contraction by stimulation of TXA /PGH2 2
eceptors [57]. The latter was also found by Kato and others [58].
A breakthrough in the EDCF topic took place with the publication
eaturing “The Janus face of prostacyclin” [59]. This referred to the], m Furchgott ‘80; Palmer ‘87; Ignarro ‘87; Khan ‘87 [6,126–128], n Katsuki ‘77a;
ds ‘98 [68], r Chen ‘88 [70], s Hickey ‘85; Yanagisawa ‘88 [43,44]. *Tracheal smooth
double role of this, traditionally regarded vasodilator prostaglandin
[23,60] which was then proposed as one of the EDCFs together
with other prostaglandins. This was not the ﬁrst time this vasodila-
tory prostaglandin had been attributed vasoconstrictive properties
[61] or even proposed as the chemical underlying EDCF [62].
What the Janus face paper introduced to the scientiﬁc commu-
nity was  the notion that all tested prostaglandins, including PGI2,
elicit endothelium-dependent contractions by converging on TXA2
receptors on the smooth muscle cell (Fig. 3). This happens in
healthy, but most especially in hypertensive arteries and explains
why many papers that appeared during the previous decade had
persistently found that cyclooxygenase inhibition or TXA2 recep-
tor blockade, but not TXA2 synthase inhibition, curtailed the
endothelium-dependent contractions [50,57,58,63].
6. Endothelium-derived hyperpolarizing factor
During the progress of EDRF/EDCF investigation, some
researchers realized that two  facts did not ﬁt in the
endothelium—smooth muscle axis that had already been estab-
lished. One was the observation that endothelium-dependent
relaxation relied on three rather than two systems. Thus, EDRF and
prostacyclin could not explain all the relaxing phenomena [64].
The second fact was the ﬁnding that the vasodilation elicited by
acetylcholine could be detected, not only on the adjacent smooth
muscle cells, but also along the arterial wall at a distance that
exceeded the range of a mere paracrine effect [65]. To sort out this
problem, the possibility that the endothelium causes electrical
changes in the nearby smooth muscle cells was considered. The
relationship between endothelial activity and myocyte hyper-
porization/relaxation was  instinctively connected to the existence
of released endothelium-derived hyperpolarizing substances,
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ad on the scientiﬁc community [6]. Before Furchgott’s discovery
here was a confusion of reports in which acetylcholine caused
ither depolarization or hyperpolarization associated with either
asoconstriction or vasodilation of smooth muscle cells. Several
xamples were referenced by Bolton [66]. In the light of the recently
nown role of endothelial cells, Gordon and Martin studied in 1983
he effects of vasodilators on calcium-activated K+ efﬂux from
ndothelial cells and its relationship with endothelium-dependent
elaxation [67]. They found an increase in this efﬂux, which is the
rst step to induce a hyperpolarization, at least of the endothelial
ell (Fig. 3). Although they did not assess membrane potentials,
hey did suggest that this cationic efﬂux might have some rela-
ionship with the relaxations. This was the prelude of the idea of
+ as the EDHF that still took some years to be considered [68].
hortly after the 1983 study, Bolton and colleagues went a step
urther showing that the inhibitory mechanical effect of carbachol,
 stable cholinergic agonist similar to acetylcholine, on smooth
uscle was associated to hyperpolarization of these cells. This
urned into depolarization when the endothelium was  removed.
hey were the ﬁrst to mention the possibility of the existence of
 factor released by endothelial cells causing hyperpolarization of
he vessel wall [66]. With all this knowledge in mind, and that of
heir forthcoming publications, Weston and others introduced to
he scientiﬁc public the term endothelium-derived hyperpolar-
zing factor or its acronym, EDHF [69]. This took place in 1988, a
ery productive year for EDHF. For example, this year Chen and
thers demonstrated the existence of a hyperpolarizing substance,
istinct from EDRF, released upon acetylcholine stimulation. Using
 K+ efﬂux marker, concluded that this substance causes myocyte
yperpolarization by opening K+ channels on the smooth muscle
ell [70] (Fig. 3). Next, Olesen and others also checked membrane
otentials, but not in the myocyte but in endothelial cells, and
emonstrated the existence of acetylcholine-activated (receptor-
perated) channels on these cells. They showed that cholinergic
timulation causes hyperpolarization of the endothelial membrane
nd suggested that this endothelial hyperpolarization somehow
ould trigger the characteristic events of endothelium-dependent
asodilator responses [71]. The real link between endothelial
yperpolarization and myocyte hyperpolarization could not be
nderstood until much later [68]. Finally, during this year of 1988,
élétou and Vanhoutte bioassayed the hyperpolarizing substances
nd provided the ﬁrst evidence of the diffusible properties of EDHF
72].
From then on, a quest aimed to ﬁnd out the chemical nature of
he EDHF(s) begun. By this time, EDRF had been already identiﬁed
s NO, so this was the ﬁrst proposed molecule. NO was initially ruled
ut [73], but later reconsidered by Tare and others proving that NO
lockers reduce acetylcholine-elicited hyperpolarization in some
rteries [74]. Sometime later, these researchers demonstrated that
ot only NO, but also prostacyclin, exhibit hyperpolarizing abilities
Fig. 3). Their proposal was  that both of them contribute to the elec-
rical phenomenon but without precluding the existence of a major
DHF [75]. Other candidates on the line were hydrogen peroxide
nd epoxyeicosatrienoic acids (EETs). Initial evidence showed that
he oxygen-derived species, hydrogen peroxide, exhibits hyper-
olarizing properties on myocytes but failed to pass the catalase
est (forced conversion of hydrogen peroxide into water by this
nzyme should inhibit endothelium-dependent hyperpolarization)
76]. However, Matoba and colleagues, nearly a decade later, suc-
eeded in this aspect and presented hydrogen peroxide as a ﬁrm
andidate for EDHF in a sequence of papers, the ﬁrst of which was
ublished in 2000 [77] (Fig. 3). Another possible EDHF was  pro-
osed in 1994. Hecker and others, on the basis of myographical
vidences, suggested that the cytochrome P450 derivatives, EETs
ct as EDHFs [78]. A subsequent report that included the assessment
f membrane potential changes conﬁrmed Hecker’s proposal [79]Research 113 (2016) 125–145
(Fig. 3). A large number of possible substances with endothelium-
dependent hyperpolarizing properties has been suggested over the
years and the whole coverage exceeds this revision. There are good
reviews on this speciﬁc topic, for example, ref. [80].
In 1998 Edwards and coworkers [68] picked up the thread of the
work on endothelial K+ efﬂux initiated by Gordon and Martin [67]
and followed by Olesen’s analyses of endothelial membrane poten-
tials [71]. They showed that hyperpolarization of smooth muscle
cells might be caused by endothelium-derived K+ and performed
a complete study of the endothelial channel source of this cation
and the sites of action on the myocytes. Speciﬁcally, they conﬁrmed
the existence of a K+ efﬂux from endothelial cells upon choliner-
gic activation via endothelial calcium-dependent K+ channels. They
also demonstrated that this ionized potassium present in the extra-
cellular space acts as the EDHF by activating inwardly rectifying K+
channels and a Na+/K+-ATPase of the smooth muscle cell mem-
brane. In Edward’s model, acetylcholine stimulation involves not
only, the hyperpolarization of smooth muscle, but also the hyper-
polarization of the endothelium (Fig. 3). This simple idea of ionized
potassium being an EDHF strongly reminds the well known text-
book concept of local blood ﬂow regulation, in which K+ along with
other metabolites cause local vasodilation. Indeed, the notion that
potassium in low concentrations is a vasodilator can be dated back
as early as 1938 [81].
With all the mentioned EDHF possibilities, the problem of the
third vasodilating factor we started with [64] had been addressed.
However, the “remote” acetylcholine vascular relaxation described
by Segal and Duling [65], did not have a satisfactory answer if
one counts only with the concept of hyperpolarization of adjacent
cells. The only apparent way to solve the obstacle was to con-
template the possibility that this change in membrane potential,
either of the endothelial cell or the myocyte, could be electro-
tonically transmitted to neighbouring cells. This is only possible
if cell membranes join together in low resistance discrete loca-
tions called gap junctions. In the case of endothelial to myocyte
junctions, the structural basis involves the approach of smooth
muscle cell membranes towards those of endothelial cells. This
was ﬁrst described by Thoma in the early twenties who claimed
to have observed cytoplasmic protrusions passing through fenes-
trae of elastic lamina which apparently contacted smooth muscle
cells [82]. The advent of electron microscopy imaging in the ﬁfties
conﬁrmed these pioneering observations [83] and a decade later
Rhodin, with improved electron microscopy images observed in
great detail these protrusions which he named “myoendothelial
junctions”. He also suggested that myoendothelial junctions may
serve as a rapid communicating pathway between circulating hor-
mones and vascular smooth muscle via endothelial cells: “. . .It
would therefore be quite advantageous if some endothelial cells could
serve as receptors [of humoral transmitter substances] which initiate
the depolarization of the smooth muscle membrane.  . .”. Thus, Rhodin
anticipated a functional role for these junctions [13]. Gap junctions
are present in numerous cell types and have been detected between
adjacent endothelial cells [84] and adjacent arterial smooth muscle
cells [85]. The mere approach of two membranes does not imply the
existence of a low resistance electrotonic connection. Gap junctions
exhibit a characteristic pentalaminar pattern in electron micro-
scope plates. Thus, bridges connecting endothelium and myocytes
can only qualify as an authentic myoendothelial gap junction when
this pattern is observed. In the case of myoendothelial connections,
his was  ﬁrst described by Spagnoli and coworkers [86].
The ultrastructure of gap junctions involves the docking of two
membrane channels, each formed by six proteins. These were ﬁrst
characterized in 1974 by Goodenough who  resolved naming then
“connexins” [87], inspired by the name “nexus”, formerly given to
gap junctions before this term was generally utilized [88]. A vari-
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intima and/or media) speciﬁcally express connexins 43 [89], 40
90], 37 [91] and 45 [92] (chronologically ordered as described,
itations refer to the ﬁrst description published). In 2006, Haddock
nd colleagues localized, by means of high resolution immunohis-
ochemistry, connexins 37 and 40 to myoendothelial gap junctions
n brain small vessels [93].
The electrotonical transmition of hyperpolarization from cell
o cell along the arterial wall was explored in profound detail by
egal and Duling’s group during the years following their acetyl-
holine report [65]. The whole picture was beautifully reviewed by
egal in recent times [94]. Therefore, the problem of transmission
as solved. Moreover, it was an incentive for some to go further
y suggesting that, with functional myoendothelial gap junctions
resent, perhaps the existence of a diffusible factor (EDHF) was not
ecessary after all. For example, Chaytor and coworkers strongly
ighlighted the role of these membrane structures in endothelium-
ependent relaxations [95]. Actually, these junction-transmitted
elaxations have been referred to as “EDHF-type” [96], for their
trong resemblance to those mediated by the released factor, and
he term EDH, rather than EDHF, is currently recommended [97].
n any case, these forms of endothelium-dependent relaxations,
eliant on myoendothelial gap junctions are not, stricto sensu,
ithin the scope of the title “paracrine control” of this review. Fig. 4
ummarizes the electrical, paracrinal and mechanical phenom-
na using tracings from different sources [68,98] and considering
ndothelial K+ efﬂux as an example of an EDHF released from
ndothelial cells upon acetylcholine stimulation.
. Search for the chemical nature of EDRF.
itrovasodilators and cyclic GMP. The link EDRF-NO
Most of the period dedicated to EDCF and EDHF research
as also devoted to try to unveil the chemical nature of EDRF.
ctually, Furchgott’s 1980 report included also a systematic
tudy of most of the possible candidates for EDRF (ruling out
yclooxygenase-dependent products and speciﬁcally prostacyclin,
radykinin, adenosine, cAMP and cGMP) and part of the arachidonic
cid/lipoxygenase line mentioned above [6]. The research on the
olecule responsible for endothelium-dependent relaxations was
specially focused on the possibility that EDRF could be a lipoxyge-
ase product of arachidonic acid [99–102]. By the mid-eighties this
ypothesis had deﬁnitely reached a dead-end. There was another
ine of evidence that, looking at it from the perspective we  have
ow, appears rather obvious, but it took years to be considered.
his was the line of nitrovasodilators and guanylate cyclase that
ommenced a decade earlier.
In the mid-seventies various groups were working on cyclic
ucleotides, especially the recently discovered cyclic GMP  (cGMP)
103]. In the process of characterization of the soluble and partic-
late fractions of guanylate cyclase (the enzyme that synthesizes
GMP from GTP) a number of chemicals were used. Among these,
urad’s group found that nitrogen compounds, such as azide
NaN3) or nitrite (NO2Na) activated guanylate cyclase [103]. Other
itrocompounds were also reported to activate the formation
f cGMP, such as nitroglycerin [104] and nitrosamines [105].
hat attracted Murad’s attention was that these nitrogen-bearing
olecules acted on guanylate cyclase in a hormone-like fashion.
n the course of this research, his group enlarged the variety of
itrogen compounds that activated guanylate cyclase [106] and dis-
overed that all these compounds yielded nitric oxide (NO) [106]
hich strongly activated guanylate cyclase and generated cGMP
106,107]. Some of these nitrocompounds were drugs known for
ore than a century for their anti-anginal [108] and vasodilatoryResearch 113 (2016) 125–145 131
properties [109]. Actually, and in parallel with the biochemical
research, the abilities of these compounds to relax various smooth
muscles and its relationship with cGMP was  also being investigated
[110–112]. Indeed, it was  then when the term “nitrovasodilator”
was introduced by Murad himself to refer to the NO-generating
drugs that elicited vasodilation [113]. By the end of the decade, the
biochemistry of guanylate cyclase activation by NO and nitroso-
compounds and its connection with smooth muscle relaxation was
quite well characterized. However, the link of NO with hormones,
sought by Murad and the biological signiﬁcance of the relationship
between NO and guanylate cyclase was still an absolute enigma as
admitted by himself [114].
During the search for the chemical identity of EDRF over the
early eighties, biochemical and physiological coincidences between
the properties of NO and EDRF were being continuously reported.
Even before the existence of EDRF was known, it was noticed that
carbachol, an agonist similar to acetylcholine, increased the tis-
sue levels of cGMP [104]. Once in the context of EDRF research, it
was reported that this transferable factor, as stimulated by acetyl-
choline, is capable of increasing the release of cGMP from arterial
strips [115]. Indeed, Murad forwarded the hypothesis that the
effects of EDRF are mediated by cGMP [116]. A year later, Ignarro
reported that the effects of both, nitrovasodilators and EDRF on
vascular relaxation and cGMP accumulation was antagonized by
the inhibitor of guanylate cyclase, methylene blue [117]. Shortly
later, the same was  published for hemoglobin [118]. In the sub-
sequent year, three suggestive papers shed light on the reason
why the lipoxygenase hypothesis for EDRF was  being so confound-
ing. Two of them demonstrated that superoxide anions destroy
EDRF [119,120]. The other, directly ascribed the effects of lipoxy-
genase inhibitors to their redox properties rather than to any
speciﬁc action on EDRF [121]. Coincidences between the biolog-
ical actions of nitrovasodilators and those of EDRF, such as that
both inhibit platelet aggregation [122,123], were being reported.
Perhaps the most peculiar coincidence was Rapoport’s ﬁnding that
both, nitrovasodilators and EDRF, induce desensitization associated
with a decrease in the formation of cGMP [124]. More precisely,
EDRF (as stimulated by acetylcholine) elicited lesser relaxing effects
after exposure to a nitrovasodilator. This meant that EDRF was
desensitized by the nitrovasodilator and thus, necessarily held a
common underlying mechanism.
It is remarkable that with all this mass of evidence, the scientiﬁc
community was so reluctant to admit that EDRF was a nitrova-
sodilator. An example of this reluctance is that even the nucleotide
cGMP was  proposed as a candidate for EDRF’s chemical nature
[115]. Still, in 1983 Furchgott wrote: “. . .EDRF, after diffusing from
the endothelial cells [. . .], stimulates the muscle guanylate cyclase
[. . .]. This speculation assumes a causal relationship between increases
in cGMP levels and relaxation in vascular smooth muscle. Evidence
consistent with such a causal relationship [. . .]  by nitric oxide [. . .]
has recently been presented [. . .]. However, [. . .], the case for a causal
relationship has not yet been proven. . . ” [125]. The reason why it
took so long to perform the experiments that proved this relation-
ship was  probably that never before a molecule of such a small
molecular weight had been regarded as a biological mediator, and
even less when the putative mediator, NO, is a toxic gas as well.
Palmer and coworkers ﬁrst reported that NO accounts for the
biological activity of EDRF in 1987 [126]. Shortly later, a paper
by Ignarro [127] and a bookchapter by Khan and Furchgott [128],
showing fundamentally the same, appeared in the press. Actually,
Ignarro’s group published numerous papers on the chemical nature
of EDRF as NO nearly at the same time [127,129–131], thus indicat-
ing that the three groups were concomitantly working in the same
topic (Fig. 3).
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Fig. 4. Electrical, paracrine and mechanical phenomena occurring upon acetylcholine administration on endothelial and smooth muscle cell membrane potentials (Vmb), K+
concentration assessed in the myo-endothelial area and arteriolar diameter. Tracings have been placed in the order of progress of events. Endothelial and smooth muscle
c ed fro



































pell  membrane potentials and arteriolar diameter are synchronous tracings modiﬁ
n  muscle feed arteries. K+ concentration, used in this case to illustrate an example
modiﬁed). Acetylcholine was administered in a regular manner on hepatic resistan
. The NO pathway
The publication of the NO identity of EDRF by Moncada’s team
126] came from a group that had not worked before in the ﬁeld
f nitrovasodilators but with prostaglandins, as stated in previous
ections. Moncada’s group took advantage of their expertise in the
ioassay cascade preparation [4], which was powerfully reinforced
ith endothelial cells cultured on beads. They had to develop new
peciﬁc methodology to assess NO release from endothelial cells.
uriously, this methodology came from the use of nitrite sensors
ased on chemiluminescence adapted from the motor industry. All
his ﬁnally allowed proving that the pharmacological properties
f EDRF and NO are indistinguishable. This was nicely reviewed
n more recent years [60]. Despite the group was a newcomer in
he nitrovasodilator ﬁeld, rapidly took the lead, especially unrav-
lling the biochemical pathway of NO synthesis and the origin
f NO as synthesized from L-arginine. The discovery served as a
trong incentive to boost the research in the NO ﬁeld as seen by the
ramatic rise in publications over the following years (Fig. 5). Evi-
ence was sufﬁcient to recognize NO as the endothelial endogenous
itrovasodilator, in the sense Murad gave to this term [113]. This,
hen speciﬁcally referring to the vessel wall [132] but, in general,
O was regarded as a ubiquitous mediator of cell communication
133].
Especially relevant to NO exploration was the research on the
ynthesis of NO from L-arginine that led to the establishment of the
O pathway. This discovery had a long history behind of various
eports on scientiﬁc topics unrelated with vascular biology and in
ome instances unrelated between each other. It just needed some-
ody to put them together and link them with EDRF. The sequence
f reports that led to the l-arginine-NO pathway started up with
 topic initially unrelated with this pathway: nitrate, nitrosamines
nd cancer. There was a long lasting debate on whether nitrate
−NO3 ) is produced endogenously by mammalian cells and if so,
ow. Measurements performed early last century indicated that
rinary nitrate had to be synthesized within the body albeit no
athway was known for the synthesis of this anion [134]. Them Emerson and Segal [88]. Acetylcholine was administered by microiontophoresis
EDHF, was  measured in the myo-endothelial space by Edwards and coworkers [68]
eries.
topic was  revisited in the late seventies by scientists concerned
about the possibility that the exposure to nitrate could yield to
the fearsome compound, nitrosamine, clearly related to stom-
ach cancer. Initially it was  hypothesized that this endogenously
formed nitrate was  the result of the metabolism of the intesti-
nal ﬂora [135], but experiments on germ-free rats showed that,
deﬁnitely, mammals were able to make themselves nitrate [136].
The following year, a clinical paper appeared reporting the exis-
tence of children with methaemoglobinemia, a condition caused,
among other factors, by high environmental exposure to nitrites
or nitrates [137]. These children exhibited a very high concen-
tration of plasma nitrate and severe methaemoglobinemia. These
observations would have nothing to do with the present topic on
the NO pathway except for the fact that those children had never
been exposed to water or food-containing nitrates. What all those
infants had in common was  that all of them suffered an acute diar-
rhoea. The possibility that a bacterial gastroenteritis was behind
the appearance of this increased endogenously-synthesized nitrate
concentration prompted Tannenbaum’s group to check this point
in animals challenged with bacterial endotoxin. The result was a
dramatic rise in nitrate production [138]. Because this appeared to
be an immune reaction, macrophages were the ﬁrst candidate cells
to be examined. Stuehr and Marletta performed the experiment in
these cells and found a sharp rise in nitrate release taking place
when cultured macrophages were treated with endotoxin [139].
At the same time another group was carrying out a line of
research, which was  also related with the immune system. Hibbs,
the senior of this group, had been interested in the interaction of
macrophages with tumour cells and the biochemistry of the acti-
vated macrophage mechanisms of cytotoxicity. It had already been
observed a long time before that arginine inhibited the growth
of tumours [140]. Aware of this, Hibbs, during the course of the
biochemical studies, observed that macrophages failed to become
active upon immunological stimulation if no amino acids were
present, but fully able to attack neoplastic cells if l-arginine, but
not the dextrorotary form, was present in the medium [141].
Intrigued with this ﬁnding, the group went on studying in depth









































tFig. 5. Pubmed impact of the main topics
he biochemistry involved. In this initial report, they found that
ethylated analogues of l-arginine inhibited macrophage induc-
ion. Further research on the arginine issue, and already knowing
bout the nitrate release from macrophages upon endotoxin stim-
lation [139], led the group to the proposal that the origin of that
itrate could be l-arginine [142]. In this paper [142], Hibbs demon-
trated that l-arginine was oxidized to nitrite and l-citrulline, and
roposed a preliminary biochemical pathway, which he recog-
ized, had never been seen before in living cells [142]. Still, these
esults did not link l-arginine with NO yet.
A piece of evidence that led to the association between nitrate,
-arginine and EDRF was disclosed because after the discovery of
DRF as NO, many groups initiated a research campaign looking for
O synthesis, not only in the endothelium, which was  the starting
oint, but also elsewhere in different organs and systems. One of
hese was the central nervous system. Inevitably, this search led
o a report published some years before by Deguchi and cowork-
rs on the activation of guanylate cyclase in brain cells [143]. By
he year this research was being carried out, Deguchi was aware
hat nitroso-compounds could activate guanylate cyclase, but what
hey were trying to ﬁnd was an endogenous substance able to acti-
ate this enzyme. They had a strong background in ﬁne chemistry,
hich they utilized. The result was that they were able to speciﬁ-
ally purify L-arginine from the brain extract. They even compared
he activation pattern of guanylate cyclase with that of nitroso-
ompounds and noticed the similarities. They also pointed out the
hemical resemblance of L-arginine and some nitroso-compounds
143]. They did not know about NO or any synthesizing pathway,
ut the data they had was remarkably close to it.
It can be seen that all the reports we have mentioned were
ublished over a very long period of time, they were appar-
ntly unrelated between each other and published in journals
evoted to different topics. Speciﬁcally selecting the right papers
t a time when computer search engines were practically inexis-
ent and putting them together in the right order appears today
ike looking for a needle in a haystack. However, this seemed
o be no handicap and it did not take long after the discovery
f EDRF’s chemical nature to identify L-arginine as the precur-
or of NO. The ﬁrst report came from Moncada’s lab [144] who
ad focused part of his research in the brain NO synthase [145]
nd noticed Deguchi’s report. At the same time, they had a long
ime expertise in the immunology/inﬂammation area [20,23] that present review over the last forty years.
helped joining together the brain guanylate cyclase report with
the different ﬁndings published earlier on endogenous nitrates and
l-arginine dependency of macrophage activation. Still, and once
again, the same idea was  pursued independently by other groups
who published shortly after. One group conﬁrming l-arginine as
the precursor of EDRF [146] and another demonstrating that NO
is the intermediate molecule between L-arginine and nitrate [147]
previously described in macrophages [142]. Fig. 6 summarizes the
three main lines of research that yielded to the ﬁrst step of the
l-arginine to NO biochemical pathway.
Quickly, l-arginine methylated analogues, already used by
Hibbs [141], were tested on endothelium-dependent relaxations to
inhibit NO synthesis [148] and the ﬁrst partial characterization of
the enzyme, which was later named endothelial NO synthase, was
performed [149] (Fig. 3). A major implication for research of the
availability of these analogues was  the possibility to leap from the
single vessel [148] to a whole organ [150] and ﬁnally to the entire
individual [151]. These two publications proved that NO, basally
released, has a permanent vasodilatory action that sets perfusion
pressure [150] and even the entire blood pressure [151] to a physi-
ological point that is very well below the pressure that would exist
without NO. These observations led to the notion of the vascular
system as a conductance, rather than a resistance system and are
clearly explained in a review published later on by Moncada [60].
All these advances ignited a rise in NO research that peaked in
1992 (Fig. 5). NO synthases were found in numerous tissues besides
the vessel wall (for review see ref. [152]) and the 1991 revision
published in Pharmacological Reviews [153] became the highest
cited paper ever in vascular pharmacology (12096 citations in a
recent search and followed by Furchgott’s 1980 paper with 6569
citations). The following year, NO was awarded the “Molecule of
the Year 1992” [154], and ﬁnally, the 1998 Nobel Prize in Physiology
or Medicine was  awarded for the discoveries concerning NO as a
signalling molecule in the cardiovascular system.
After 1992, research in the NO ﬁeld was vertiginous. To mention
just a couple of examples on how the newly incorporated biochem-
ical route of l-arginine affected the map  of biochemistry known by
that time, it is worth making an allusion to endothelial arginase and
endogenous arginine derivatives. Before the l-arginine-NO path-
way was incorporated to the textbooks, the hepatic urea cycle was
the major known destiny of arginine via the arginase reaction.
It was eventually noticed that endothelial cells possess arginase


































hig. 6. Three unrelated lines of research (nitrovasodilator, nitrate/nitrite and argin
oncurrent publications are cited in publishing order.
ctivity and produce urea [155]. It was suggested [156], and more
ecently proven [157], that the role of endothelial arginase is to
egulate the substrate provision for endothelial NO synthase and,
hus, NO-dependent relaxation. Another remarkable aftereffect of
he newly acquired knowledge in arginine biochemistry was the
ecovery of very old reports on the presence of endogenous argi-
ine derivatives in the urine [158]. This was of enormous interest
nce known that l-arginine analogues inhibit NO synthesis [148]
ecause it represented the possibility that NO synthase inhibitors
ere, not only drugs, but physiological actors of the l-arginine-
O pathway, the so-called endogenous inhibitors of NO synthase.
he ﬁrst of these, asymmetrical dimethylarginine (ADMA), was
etected by Vallance and colleagues in human urine [159] and later
n human endothelial cells [160]. These two natural controllers of
he NO pathway, endothelial arginase and ADMA, have been exten-
ively studied from a cardiovascular disease point of view that
xceeds the limits of our review.
At this time point, the 3 major endothelium-derived paracrine
asoactive substances (EDRFs, EDCFs and EDHFs) were perfectly
atalogued (Fig. 3). One aspect that tempted vascular physiologists
as to compare each of them in different vascular beds, most partic-
larly, in conductance versus resistance vessels. Furchgott veriﬁed
rom the very beggining of his research that EDRF release takes
lace, not only in large conductance vessels where he made the
iscovery [6], but also in arteries small enough to control regional
lood ﬂow [161]. Once NO synthase inhibitors became available,
t did not take long to realize that these inhibitors were more efﬁ-
ient in large compared to smaller arteries [162], something that
as ascribed to a differential role of NO versus EDHF in large andmall arteries, where the importance of EDHF increases as the ves-
el’s calibre diminishes [163]. This notion conﬁrmed the earlier
lectrophysiologist’s ﬁnding that microvascular endothelial cells
yperpolarize upon agonist stimulation more efﬁciently than thesearch) led to the discovery of the L-arginine to NO pathway in 1988. Same year
macrovascular do [164]. In practice, however, both NO and EDHF
have demonstrated to be key elements of the circulatory control
in vivo [151,165].
9. Adventitia and periadventitial adipose tissue
It can be noticed that, so far, the leading character in the
paracrine control of the vessel’s function has been exclusively
attributed to the endothelium, with NO at the front as the canon-
ical vasodilator. The abluminal layer, the adventitia, had been
generally overlooked. This scenario is now changing. While the
textbook paradigm holds that the vascular wall consists of tuni-
cae intima, media and adventitia,  a forth layer, the tunica adiposa
has been recently claimed [166,167] on the basis of the clear inﬂu-
ence that periadventitial adipose tissue has on vascular function.
Thus, perivascular adipose tissue (PVAT), up to now regarded as
“extravascular”, is being increasingly considered an “intravascu-
lar” structure. While some talk about four layers [166–168], others
prefer to consider the existence of three, and divide the third
one in “adventitial compacta” and “adventitial fat” or PVAT [169].
The “compacta” is the classical adventitia and is made mostly
by ﬁbroblasts, but also macrophages, dendritic cells, progenitor
cells, vasa vasorum endothelial cells, pericytes and nerve end-
ings [170]. The tunica adiposa or PVAT is mostly formed by white
or brown adipocytes (depending on the depot), but also by the
so-called stromal vascular fraction, which includes preadipocytes,
ﬁbroblasts, mesenchymal stem cells, lymphocytes, macrophages,
nerve endings and vasa vasorum endothelial cells [171]. As for the
nerve endings, these are loose varicose sympathetic or parasympa-
thetic autonomous ﬁbres. The two may  innervate smooth muscle
cells but adipocytes are mainly sympathetically innervated [172].
Whether adipocytes receive parasympathetic innervation is a mat-



























































adipose depot [196–199] and this confers differences in the ability
to control the underlying vessel [200]. This reminds very much the
well know heterogeneity the endothelium exhibits in the kind of
1 A dysfunctional PVAT has hypertrophied, lipotoxic adipocytes, a condition gen-
erally occurring in visceral adipose tissue upon a lipid overﬂow due to the positiveE. Nava, S. Llorens / Pharmacol
ayers of the adventitia, in this review we will simply name “adven-
itia” to the tunica adventitia stricto sensu and “PVAT” to the new
unica adiposa or outermost limits of the vessel.
The reason why the adventitia has received little pharmacologi-
al attention as compared to the endothelium relies on the technical
ifﬁculties to remove it properly [175] so as to investigate its roles
n a similar fashion as it was done with the endothelium. In con-
rast, PVAT is fairly easy to remove and, paradoxically, this is the
eason why it took so long to notice its vasoactive roles. In the large
ajority of myographic studies perivascular fat is removed on a
outine basis. This practice is based on the assumption that PVAT is
 extraneous tissue and, worse, may  impede the diffusion of vasoac-
ive substances to the “authentic” vascular tissue, as explained by
esearchers in the PVAT ﬁeld [176].
0. The paracrine role of the adventitia
If the endothelium was once considered a “tapestry”, the adven-
itia has been generally regarded as a mere connective support of
he vessel with no active role to be sought in. Possibly the ﬁrst study
o introduce an active role on vascular function was  the discovery
n 1995 of a powerful superoxide-generating system within the
dventitia [10]. However, prior to this year, few scattered studies
evealed some abilities of adventitial cells with regard to various
asoactive substances such as prostacyclin [26], histamine [177],
ngiotensin converting enzyme [178], traces of angiotensinogen
179] or serotonin [180]. Shortly before the adventitial superox-
de preliminary ﬁnding [10], a suggestive study was published on
 possible functional activity of adventitia, in this case as a bar-
ier speciﬁcally arranged against endothelial NO [181]. Pagano’s
tudy on adventitial superoxide generation was followed by a series
f reports that increasingly clariﬁed this topic: the NADPH oxi-
ase, responsible for superoxide generation, was  pinpointed to the
dventitial ﬁbroblasts [182] and the functional barrier described by
teinhorn and others was imputed to this superoxide for its role in
nactivating NO [183]. In 1999, it was stated that adventitial super-
xide does play a paracrine role [184]. Therefore, the adventitial
broblast began to qualify as a paracrine cell, at least in what vaso-
otion is concerned. In the meanwhile, it was  reported that the
dventitia is able to generate NO, but only when challenged with
ndotoxin [185,186]. It must be remarked that ﬁbroblasts seem to
e unable to produce NO without prior induction [187].
The technical difﬁculties to obtain vascular preparations devoid
f adventitial cells have been overcome by various means. One
s a curious set-up in which the artery ring is pharmacologically
ssessed inside-out with the adventitia facings outwards [183] or
ombining physical removal with collagenase treatment [188]. This
atter method permitted to observe that the adventitial layer allows
or stronger smooth muscle contractions (Fig. 7D) and smaller
ndothelium-dependent relaxations, thus clearly establishing a
ole for the adventitial layer in the regulation of the vascular wall
188]. The impact the adventitia has on endothelial function was
gain ascribed to superoxide’s action [189] and more recently to
ydrogen peroxide [190]. Additionally, it has been demonstrated
hat ﬁbroblasts produce endothelin-1, thus including this peptide
o the short list of adventitial paracrine vasoactive substances [191].
1. The paracrine role of PVAT
Before today’s interest in PVAT became commonplace,
dipocytes were already known to synthesize and release
ormones related to energy homeostasis and, together with
acrophages, operate as immune cells. This, due to their ability to
roduce cytokines, in this case, adipocytokines, which are largely
he same ones as those produced by genuine immune cells [192].Research 113 (2016) 125–145 135
The novelty actually was the suggestive possibility that adipocytes
acted as paracrine cells to the vessel wall by releasing transfer-
able substances with vasomotor abilities. Obviously, this is only
possible when adipose tissue is close to the artery, a circumstance
that only happens in the case of adventitial fat, that is, PVAT. In
this sense, adipocytes would operate in conjunction with intimal
endothelial cells. This idea was  materialized by Löhn and colleagues
who ﬁrst demonstrated that the adipose tissue surrounding the
adventitia is able to release a transferable factor that affects vascu-
lar tone. In 2002 they published the existence of a diffusible factor
derived from PVAT, which received the evocative name of ADRF, the
acronym of “adventitium-derived relaxing factor” [9]. In a follow-
ing paper of the same group, they decided that the “A” should stand
for adipocyte instead of adventitium [193] and from then on, both
names have been used indistinctly, with the common acronym of
ADRF. In these ﬁrst reports, they demonstrated that dose-response
curves to various vasoconstrictors (phenylephrine, angiotensin II
and serotonin) were systematically smaller when the arterial seg-
ment was tested without dissecting off the perivascular fat (Fig. 7C).
They also showed that Krebs buffer collected from an artery incu-
bated also in these conditions, i.e. with PVAT, was able to elicit a
relaxing response when added to a segment fully dissected and
precontracted with one of the vasoconstrictors [9,193].
In the following lines we  will review the historic progress of
this idea, which has yielded to a new vision of the vessel, both
functional (perivascular adipocyte working in conjunction with the
endothelial cell) and morphological (the recent inclusion of PVAT
as the fourth layer of the vessel’s histology) [166–169]. Even patho-
physiological: a “perivascular adipose tissue dysfunction” has been
proposed [194].1 Furthermore, the ultrasonographic measurement
of the adventitia/media thickness (which includes PVAT) has been
proposed as an alternative to the traditional intima/media thick-
ness to predict cardiovascular risk [195].
Although a great deal of enthusiasm has been placed on PVAT
as an alternative paracrine source of the vessel wall, before going
on, it is important to emphazise that there are major differences
between the endothelial tissue and PVAT. Aside from the obvious
fact that endothelial cells are directly subjected to the inﬂuence of
the blood stream, the ﬁrst dissimilarity between both tissues is that
intimal endothelial cells are (or should be) always present in what-
ever kind of vessel and in the entire circulation. In contrast, PVAT
is absent in numerous vessels. Large conduit arteries and veins are
generally surrounded by the adipose tissue they run through, but
this is normally left behind once they penetrate into an organ. Cere-
bral blood vessels typically lack PVAT. Additionally, if we  consider
that the whole pulmonary and systemic capillaries (except those
that irrigate fat depots) are completely devoid of adipose tissue,
this relegates PVAT to a relatively small proportion of the circula-
tory system. A second difference is that, while PVAT is comprised
by numerous cell types (see classiﬁcation in ref. 171), the tunica
intima is, in physiological conditions, made exclusively by endothe-
lial cells and some subendothelial ﬁbroblasts. On the other hand,
both tissues have things in common. For example, PVAT has large
phenotypic differences depending on the speciﬁc location of a givenenergy balance of obesity. These visceral adipocytes exhibit an abnormal pattern of
adipokine secretion. The extrapolation of this condition to the adventitial adipocytes
makes PVAT a dysfunctional one in that there is an excess in adipocytokine secretion
and an undesirable release of vasoactive adipokines both with unhealthy conse-
quences for vascular function.
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Fig. 7. Contractile responses obtained with noradrenaline or phenylephrine by Soltis and Cassis (A and B), Löhn and colleagues (C) and Somoza and others (D) in aortic (A, B
and  C) and carotid segments (D) showing: 1) PVAT’s nerve endings noradrenaline recaption effect (A and B), 2) the anticontractile effect of PVAT (C) and the procontractile
effect  of adventitia. Observe that Soltis and Cassis did not ﬁnd any effect of PVAT on phenylephrine contractions, an observation attributed to the lack of recaption by PVAT’s
nerve  endings (B). This recaption does take place when the vessel is challenged with noradrenaline (A), but not with phenylephrine (B). Löhn and colleagues were able to
d heny


























temonstrate the release of an anticontractile substance from PVAT in response to p
unica  adventitia exhibits procontractile properties in the same artery [188] as we
D). + = tissue present. − = tissue removed.
ubstances released depending on the vascular region [41]. Another
roperty shared with endothelial cells is the ability to synthesize
rostaglandins and NO. General adipose tissue releases NO [201]
nd prostaglandins [202]. PVAT in particular, also releases these
wo substances [203,204].
The ﬁrst description of the modulatory action of perivascular fat
n vascular contractility was reported eleven years before Löhn’s
ublication, by Soltis and Cassis [8]. This work has been sometimes
isinterpreted as the ﬁrst postulator of a prorelaxing role of PVAT.
ctually, what these researchers describe is PVAT as the physical
arrier of sympathetic recaption by these nerve endings, which
re present both in the adventitia and in PVAT. Soltis and Cassis
bserved an abolishment of noradrenaline-mediated contractions
electric or tyramine stimulation) in the absence of PVAT and a
ecrease in the sensitivity to noradrenaline itself when aortic seg-
ents have an intact PVAT (Fig. 7A). They elegantly demonstrated
hat this is caused by the uptake and removal of this particular
atecholamine by adipose tissue and suggested that the nerve end-
ngs within PVAT recapt and eliminate noradrenaline present in
he synaptic gap. This, understandably, ends up in a buffered effect
f this effector, but they never stated that PVAT releases any sort
f relaxing or anticontractile factor. In fact, they did demonstrate
hat the experiment worked only with noradrenaline, which under-
ent recaption, but not with phenylephrine or potassium, which
id not (Fig. 7B). It must be noted, however, that in addition to
hese observations, Soltis’s paper anticipated in nearly two decadeslephrine stimulation (C). In sharp contrast with the tunica adiposa or PVAT (C), the
arotid artery (D). Graphs reconstructed from ref. [8] (A and B), [9] (C), and [187]
the possibility that angiotensin II of PVAT’s adipocytic origin inﬂu-
ences vascular tone [205]. This idea was also proposed in a previous
work by the same group showing the presence of high levels of
angiotensinogen mRNA in aortic PVAT [179].
12. Identity and mechanism of action of PVAT’s paracrine
substances
Adipose tissue has progressively gained the category of
endocrine gland in a similar fashion as the endothelium once had
[7,206]. The substances synthesized and released by adipocytes,
collectively known as adipokines [207], exceed the hundred in
number [208]. Considering that adipocytes represent >60% of adi-
pose tissue [209] and the enormous hormonal potential these cells
possess, it is quite reasonable to assume that some adipokines,
when released from adipocytes anatomically close to the vessel
(within PVAT), reach the tunica media, or even the endothelium
and the blood stream, and affect vascular function. This assumption
inspired Yudkin and others to coin the term “vasocrine”, referring
speciﬁcally to the paracrine communication between PVAT and
the artery it surrounds [210]. Amongst the catalogued adipokines,
many exhibit vasoactive properties to some degree besides their
main function. This text does not attempt to fully describe the
vascular-related ﬁndings of each adipokine. Excellent reviews on
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erform a rough classiﬁcation of adipokines from the vascular phys-
ologist’s point of view, as follows:
) Vessel-targeted substances with uncertain chemical identity specif-
ically studied in PVAT.
) Adipokines implicated in energy homeostasis.
c) Classic vasoactive hormones with adipocytic origin.
) Adipocytokines or pro-inﬂammatory cytokines.
) Reactive oxygen species.
Vasoactive adipokines can be sorted as well considering
hether the vasomotor action takes place directly on smooth
uscle cells o via activation (or inhibition) of the release of
ndothelium-derived vasoactive substances. This aspect will be
lso taken into account.
) Vessel-targeted substances with uncertain chemical identity specif-
ically studied in PVAT
The existence of these substances is known through experi-
ents in which a physiological solution containing undissected
9] or dissected [212] PVAT of a particular artery is transferred to
nother artery devoid of PVAT that, in response, elicits a vasodi-
ation. This kind of experiment proves that the adipokines in
uestion are released by PVAT and are transferable. Presumably
hese adipokines are speciﬁcally released by PVAT and speciﬁcally
argeted to the PVAT’s surrounding artery, but whether other fat
epots release adipokines with the same properties has never been
tudied. The chemical identity of the adipokine(s) is unclear but
ften proves to relax the vessel by hyperpolarization after opening
otassium channels of different kinds on the smooth muscle cell.
s explained before, when they were discovered, these substances
ere collectively named adventitium- or adipocyte-derived relax-
ng factors (ADRFs) [9,193]. The presence of ADRF is frequently
emonstrated in experiments in which a vessel is subjected to a
oncentration-response curve to a vasoconstrictor (Fig. 7C) and,
hus, they are sometimes refered to as anti-contractile substances.
The initial reports on the discovery of ADRF already pointed
ut that the anti-contractile transferable substance is able to
pen K+ATP channels and this action is dependent on extracel-
ullar calcium, tyrosine kinase and protein kinase A, while being
ndothelium- and perivascular nerve-independent [9,213]. This
as demonstrated in rat aorta. When other vascular beds were
nder study, different channels were found to be involved. K+V
elayed rectiﬁer channels were proposed in the rat mesenteric
rtery [193], while K+Ca channels were the target of the very ﬁrst
tudy on ADRF carried out in human arteries. This was  performed by
ao and colleagues [214]. Curiously, this group, when working on
at mesenteric arteries found that the presence of PVAT augmented,
ather than diminish, contractions caused by electrical stimulation
215]. They argued that this is a speciﬁc phenomenon taking place
n perivascular nerve endings within PVAT and this action would
e mediated by superoxide anion produced by NAD(P)H oxidase
215]. In a review written later, Gao proposed to call perivascu-
ar adipocyte-derived constricting factor (PVCF) to substances of
his kind so as to distinguish them from ADRF. More recently, this
as also been refered to as “adipose-derived contracting factor”
ADCF) [216]. Gao suggested that not only superoxide, but other
ubstances could act as PVCFs, thus PVAT would elicit a dual, anti-
ontractile and pro-contractile action on the vessel it surrounds
217]. Later research demonstrating that the substance released
y adipocytes upon electrical stimulation is angiotensin II [205],
onﬁrmed Gao’s suggestion of a PVCF different from superoxide.
n the mean time, Gao kept working on the inﬂuence of PVAT
n other vascular beds. His group reported that rat aortic PVAT
eleases a transferable factor that operates under two mechanisms.Research 113 (2016) 125–145 137
One mechanism would be endothelium-independent but, unlike
ADRF reported in 2002 which depended on potassium channel
opening, they found it would be (or depended on) H2O2. Another
mechanism would cause the opening of potassium channels but,
in contrast to the initial report on rat aortic PVAT, this mechanism
is endothelium-dependent and, in this case opens K+Ca, not K+ATP,
channels [218].
Although the existence of transferable factors from PVAT is
indisputable, opinions on the identity and mechanism of action
are heterogeneous. Löhn and Dubrovska initially discarded NO,
prostaglandins and other mediators by using speciﬁc inhibitors
[9,213]. Possibly the ﬁrst attempt to pinpoint a particular substance
was that of Gao and coworkers with H2O2 [218]. However, they did
not propose a ﬁrm candidate until two years later showing that the
identity of the factor responsible of the endothelium-dependent
effects they detected is angiotensin 1–7 [219]. By the same year,
another proposal was  published: the gas H2S, via K+ATP channels
[220]. Later, another group asevered that the fatty acid, palmitate
is the ADRF acting through K+V channels [221]. Finally, adiponectin,
which had been already ruled out as an ADRF [222], came again into
scene through two  2013 publications showing that adiponectin
is an ADRF causing anticontractile effects by opening K+Ca chan-
nels [223,224]. Whatever the nature of ADRF, potassium channel
opening has been repeatedly shown as a mechanism underlying
the action of this factor. The ﬁrst to positively conﬁrm that the
anti-contractile effect is accompanied by a hyperpolarization of
the smooth muscle cell membrane were Dubrovska and colleagues
[213]. Years later, Weston and others proposed the acronym of
adipocyte-derived hyperpolarizing factors (ADHFs) to refer to the
anticontractile substances that relax the vessel’s smooth muscle
cell by means of membrane hyperpolarization [224].
b) Adipokines implicated in energy homeostasis
These are proteins involved in energy balance, insulin resis-
tance, diabetes or obesity which have shown inﬂuences on
vascular function as well. This group includes leptin, adiponectin,
chemerin, omentin, apelin, resistin and visfatin. Leptin is the major
adipocyte-derived hormone involved in the control of food-intake
homeostasis. Leptin was  also the ﬁrst adipokine reported to inﬂu-
ence vascular function. The discovery that leptin receptors are
present on endothelial cells [225] made the vascular wall a poten-
tial target of this hormone. This was  originally noticed by Frühbeck
who suggested that leptin induces the release of NO [226]. The
paracrine actions of leptin on the vessel wall are not easy to estab-
lish on the basis of what has been published since reports on
the vascular actions of this adipokine are conﬂicting. The ear-
liest reports show that leptin elicits NO-dependent [227] and
−independent [228] vasodilation, which is difﬁcult to reconcile
with the epidemiological data repeatedly showing that leptin is
linked to the cardiovascular malfunctions of obesity (For review
see ref. [211]). Studies carried out speciﬁcally with PVAT have
demonstrated that PVAT-derived leptin clearly causes endothe-
lial dysfunction in the obese animal (not the control counterparts)
[229]. However, numerous studies suggest the possibility that lep-
tin could be an endothelium-dependent ADRF [230–232]. In this
sense, leptin has been considered a paradoxical substance in that it
causes NO-dependent vasodilation and, at the same time, its very
presence impairs endothelium-dependent relaxations [233].
Adiponectin is well known by cardiovascular epidemiologists as
the adipokine that opposes leptin’s actions [211]. An excess of this
one and a shortage of adiponectin has been associated with the vas-
cular undesirable effects of obesity [211]. Adiponectin has shown
endothelial NO stimulating activity [234,235] and NO-dependent
vasodilating actions [236]. Such is the vasodilatory reputation
of adiponectin that it has been proposed as the unidentiﬁed
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Table 1
Major events of perivascular adipose tissue (PVAT) research and discovery arranged in chronological order.
Event Year References
First report on smooth muscle responsiveness and the presence of PVAT 1991 [8]
First report of the existence of an anticontractile transferable substance released from PVAT and coining of the term: ADRF 2002 [9]
Demonstration that ADRF hyperpolarizes smooth muscle cells 2004 [193]
First report on PVAT in obesity and incorporation of the acronym “PVAT” in the literature. 2005 [176]
First report of a PVAT-derived transferable relaxing substance in human vessels 2005 [214]
First report of the existence of a procontractile transferable substance released from PVAT 2006 [215]

















































mHistological recognition of PVAT as the fourth layer of the vascular wall: the tunic
The term “PVAT dysfunction” is introduced in the literature.
Incorporation of the term ADHF 
ubstance behind ADRF [223,224]. In sharp contrast to adiponectin,
hemerin, has been shown to be a PVAT-derived adipokine with
ro-contractile [237] as well as endothelium dysfunctioning [238]
roperties, operating possibly via NAD(P)H oxidase [239]. Vis-
atin of PVAT origin has shown no effects on contractility [240]
ut, in non-PVAT set ups, visfatin elicited strong endothelial func-
ion impairments [241]. Finally, omentin and resistin have not
een tested in PVAT but it has been reported that resistin impairs
ndothelial function [242] and omentin causes mild endothelium-
ependent relaxations [243].
) Classic vasoactive hormones with adipocytic origin
These are vasoactive endocrine or paracrine hormones generally
nown for being released from glands or tissues different from adi-
ose tissue (e.g.: angiotensin II or NO) but were later demonstrated
o have an adipocytic origin as well. The discovery that adipocytes
re able to synthesize and release classic vasoactive hormones
aralleled the progressively enlarging list of adipokines. To date,
raditional vasoactive substances that happen to be adipokines
t the same time are: NO, prostacyclin, prostaglandin E2, TXA2,
ndothelin-1, angiotensin II, aldosterone and noradrenaline. First
eports on the synthesis and release of the vasoactive substance
n question, either carried out using adipocytes from adipose tis-
ue (AT) other than PVAT, or using PVAT itself, are the following:
O from AT [201] and NO from PVAT [203]. Prostacyclin from AT
244] and from PVAT [204]. Prostaglandin E2 from AT [202] and
rom PVAT [245,246]. TXA2 from AT [247] and from PVAT [216,245].
ndothelin-1 from AT [248] and from PVAT [245]. Angiotensin II,
oth from AT and from PVAT [249]. Aldosterone from AT [250] (no
eport on PVAT). Finally, noradrenaline from AT [251] and from
VAT [252]. It is remarkable that some of the reports are really old,
uch as the adipocytic synthesis of prostaglandins [202], but not
ntil recently these were recognized as PVAT-derived adipokines
204,216,245]. Also longstanding is the recognition that adipocytes
re able to synthesize angiotensinogen [253] as well as the suspi-
ion that adipose tissue would be able to produce angiotensin II
8]. The fact that PVAT releases the same substances that were sup-
osedly produced by the endothelium has numerous implications,
ostly studied in the context of obesity, and exceed the capac-
ty of the present review. As mere examples, notice the relevance
hat a PVAT of the visceral fat depot would have for the obese per-
on when proven able to compete with the vascular endothelium
or the release of major vasoconstrictors like endothelin-1 [248]
r TXA2 [216,245]. Or the fact that adipocytes within PVAT releases
ngiotensin II towards the surrounding vessel, thus adding up to the
ame vasoconstrictor released from adrenal glands or elsewhere.
he same can be said about aldosterone. Indeed, it is now recog-
ized that the adipocyte is provided with the complete synthesizing
achinery of the renin-angiotensin-aldosterone system [249,250].
Another remarkable fact of PVAT, although only one report in
ice aortae exists, is that it is able to produce sufﬁcient NO to relaxosa 2007 [167]
2007 [194]
2012 [224]
an acetylcholine-stimulated deendothelialized artery [254]. If this
is conﬁrmed, it would imply that PVAT possesses much more than
a casual ability to affect the vessel’s function by substances that
otherwise all adipocytes produce. PVAT would possess a role in the
control of the vascular tone nearly as speciﬁc as that of the endothe-
lium. That adipocytes are metabolically responsive to acetylcholine
is known since the sixties [202]. It would be interesting to inves-
tigate the pathways linking muscarinic receptors and NO synthase
and whether other classical endothelium-dependent vasodilators
can stimulate PVAT to release NO. In relation to all this, it has been
proposed that PVAT-derived NO would play a transitory adaptive
role in the early stages of obesity [255].
d) Adipocytokines or pro-inﬂammatory cytokines
Adipocytokines are cytokines synthesized and released by
adipocytes [207]. These substances are normally produced in
inﬂammatory conditions, induce the formation of NO by the
inducible form of NOS [256] but impair endothelium-dependent
relaxations [257]. Adipocytes within PVAT are also able to produce
these substances. In fact, the PVAT fat store displays a particu-
larly proinﬂammatory phenotype compared to the subcutaneous
depot, and releases more adipocytokines [196]. This is true in
a normal situation [196], but is exacerbated in injurious condi-
tions [258]. Therefore, and using the title of the ﬁrst report on
cytokines and endothelial function [257], PVAT must have “an anti-
EDRF effect”. This intuitive idea has been proven in experiments
performed in arteries studied with or without PVAT [259] and
speciﬁcally related to tumor necrosis factor- [260]. It must be
emphasized, however, that not every report conﬁrms that PVAT is
a detereous tissue merely for having a basal adipocytokine releas-
ing ability. For example, Rittig and others stated that PVAT causes
no endothelial dysfunction [261] and various studies indicate that
endothelium-dependent relaxations are not altered in vessels with
a preserved PVAT as compared to vessels without PVAT [245,262].
Rather, endothelial dysfunction is detected when this experiment is
performed in obese animals [245,262]. The obese, in turn, exhibit a
loss in anticontractile function that can be improved with cytokine
antagonists [263].
e) Reactive oxygen species
Following a similar scheme as with other adipocyte-derived
substances, production of reactive oxygen species was originally
described in adipocytes many years before the concept of PVAT
existed. In this case, it was  H2O2 released as a byproduct of
adipocyte’s glucose metabolism [264]. The ﬁrst to link PVAT with
free radicals were, as previously stated, Gao and coworkers with
H2O2 in the role of a vasodilator [218] and later, superoxide acting
as a vasoconstrictor [215]. A recent study emphasizes the role of
dismutation of procontractile mitochondrial superoxide into anti-
contractile H2O2, thus reconciling the conﬂict [265]. The increase in
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Table  2
Substances released by PVAT, which have shown to relax, contract or cause endothelial dysfunction of the surrounded vessel.
PVAT-derived relaxing adipokines References PVAT-derived contracting adipokines or adipokines producing endothelial dysfunction References
Unidentiﬁed [9,193] Superoxide anion [215]
Angiotensin 1-7 [219] Visfatin [240]c
H2S [220] Angiotensin II [205]
Palmitate [221] Leptin [229]
Prostacyclin [204] PGE2 [245]
Leptin [231,232]a TXA2 [216,245]
Adiponectin [223,224] Endothelin-1 [245]d
PGE2 [246] Chemerin [237,238]
NO [255]b Noradrenaline [252]
TNF [266]e
References for vasoactive hormones do not necessarily coincide with those quoted in section 12c (Classic vasoactive hormones with adipocytic origin), which refer to ﬁrst
reports on the ability of PVAT to produce the substance but with no further attempt to study its vasomotor function.
























2b Gil-Ortega and coworkers do report functional PVAT-derived NO but in obese, n
c PVAT-derived visfatin causes no vasomotor effects but vessels incubated with t
d Only obese animals and pharmacologically, not analytically, tested.
e Especially in obese animals.
uperoxide production by PVAT has been linked to the vascular mal-
unctions of obesity such as failure of anti-contractile activity [263]
nd endothelial dysfunction [262]. Most authors coincide in that
he superoxide-generating enzyme in PVAT is NAD(P)H oxidase
215,266]. Many obesity papers tend to report together the exces-
ive production of adipocytokines and oxygen radicals [262,263],
ut only Virdis and colleagues demonstrate a cause-effect relation-
hip between tumor necrosis factor- and reactive oxygen species
roduction in PVAT [266].
Table 1 shows the principal milestones of PVAT research and
iscovery and Table 2 summarizes the substances released by PVAT
hich have shown to relax, contract or cause endothelial dysfunc-
ion of the surrounded vessel. For the sake of caution, substances
re refered to as relaxing or contracting adipokines, rather than call-
ng them ADRF or PVCF because the quoted reporting paper often
oes not do so, or simply states that the substance under test is a
andidate for ADRF or PVCF to be considered.
ig. 8. Interactions PVAT adipocyte-smooth muscle cell-endothelial cell exhibit a patter
ate  involves adiponectin, leptin, angiotensin 1–7 (AT1-7), reactive oxygen species (ROS) a
eceptor (NPR-A), adiponectin receptor (AdR), calcium-dependent K+ channel (KCa), lept
mooth  muscle cell (SMC), endothelial cell (EC).
eference matching (ﬁrst author followed by year): a Withers 2014a [270], b Withers 2014b
012  [231], g Lee 2009 [219], h Gao 2006 [215], i Virdis 2015 [266], j Antonopoulos 2015n animals.
ipokine suffer severe endothelial dysfunction [241].
13. Interactions between PVAT, smooth muscle and
endothelium
The classic vision of the paracrine control of the vessel wall
implicated an inside-to-outside signaling via prostacyclin, NO,
EDHF or EDCFs. The irruption of PVAT and its ability to signal
inwards has complicated the scenario. A possible crosstalk between
endothelial cells and adipocytes was actually proposed very much
earlier than PVAT was  described [267]. In addition, a review was
published in the early nineties defending the idea that adipocytes
are the source of arachidonic acid for endothelial prostaglandin
synthesis and, therefore, that endothelial prostaglandin release
requires the cooperation between both cell types [268]. Since
the surge of these early notions, our knowledge on the coop-
eration between the different vascular cells has grown notably.
Fig. 8, depicts the interactions described so far between the 3
cell types. Most of them have been previously described in the
n of “outside-to-inside-to-outside” communication. The trio crosstalk reported to
nd TNF. Noradrenaline (NA), 4-hydroxynonenal (4HNE), type A natriuretic peptide
in receptor (OB-R), Mas-related G protein-coupled receptor (MasR), oxidase (ox),
 [269], c Lynch 2013 [223], d Weston 2013 [224], e Payne 2010 [229], f Galvez-Prieto
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orresponding adipokine section. Interesting complex interactions
ecently proposed are: 1) axis comprised by sympathetic nora-
renaline – adipocyte 3 receptor – PVAT adiponectin – endothelial
diponectin receptor – NO – smooth muscle cell relaxation [269]; 2)
xis comprised by blood atrial natriuretic peptide – adipocyte ANP
eceptor – PVAT adiponectin – endothelial adiponectin receptor –
O – smooth muscle cell relaxation [270]; and 3) axis comprised
y smooth muscle cell-derived ROS – blood 4-hydroxynonenal –
VAT adiponectin – endothelial (and smooth muscle cell) NAD(P)H
xidase inhibition – NO – smooth muscle cell relaxation [271]. A
nal potential route of cell communication is that of endothelial
ells towards PVAT adipocytes. A recent report on this route inves-
igated the possible action of endothelium-derived NO on adjacent
VAT compared to that on the media layer. However, it failed to
onﬁrm any endothelium – PVAT axis [272].
4. Perspectives
The present review intended to provide a wide vision on the
ootsteps walked to reach the point we are now on vascular phys-
ology research. As the reader has seen, advances took place in a
ery heterogeneous manner, serendipitous in some occasions and
learly targeted in others. Some times, ancient unconnected knowl-
dge was retrieved and used in a different context to that in which
t was originally published. In other occasions, researchers were
lose to a discovery but just missed it. Attempting to provide future
erspectives is a difﬁcult task. Fig. 5 shows that research in vascu-
ar pharmacology has followed various waves in which a certain
ubstance or substances were on top. Now we are clearly in the
PVAT wave” and the nearest perspectives will likely concern the
hysiology and pathophysiology of PVAT-derived substances. The
ollowing are some questions raised in the course of this review
hich may  be useful for forthcoming research: Is PVAT-derived
O able to compete with endothelium-derived NO in the con-
rol of basal vascular tone, obviously, in vascular beds that carry
dipose tissue around? Alternatively, is PVAT-derived NO able to
eplace endothelial NO in dysfunctional conditions? Is endothe-
ial dysfunction of a certain artery necessarily accompanied by
VAT dysfunction of this particular vessel or, rather, a functional
ndothelium or PVAT can replace the dysfunctional counterpart?
re PVAT-derived prostaglandins and (or) ADRF (which in prac-
ice is an ADHF) able to compete with the endothelial counterparts,
rostacyclin, thromboxane A2 and EDHF? In general terms, to what
xtent PVAT exerts a regulation in vasomotion as compared to
ndothelial cells? Is PVAT-derived NO able to relax deendothelial-
zed arteries upon classic endothelial stimulators like acetylcholine
r bradykinin or should we look for PVAT-speciﬁc NO stimulators?
hat are the similarities and differences between the biology and
egulation of endothelium-derived NO and that of NO released from
VAT? Is ADRF exclusively released from PVAT, or other fat depots
o so, and thus, ADRF is an unspeciﬁc adipokine? Does the general
ule stating that the lesser the caliber or a vessel, the higher the ratio
DHF/NO apply for PVAT as well regarding ADHF versus adipocytic
O? Are there endothelium-derived substances targeted to adja-
ent PVAT or is smooth muscle the exclusive target of endothelial
ells?
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